Cargando…

Interaction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT)

Stem cell transplantation affects patient׳s vulnerability to infections due to immunological changes related to chemotherapy. Multiple myeloma is characterized by susceptibility to infections, and IL-6 and TNF-α increased levels affect immune response (IR). Polymorphisms in promoter region of cytoki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trigo, Fernanda M.B., Luizon, Marcelo R., Dutra, Hélio S., Maiolino, Ângelo, Nucci, Márcio, Simões, Belinda P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216334/ https://www.ncbi.nlm.nih.gov/pubmed/25379407 http://dx.doi.org/10.1016/j.lrr.2014.05.002

Ejemplares similares

Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma
por: Al-Mansour, Zeina, et al.
Publicado: (2014)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial
por: Gimsing, P, et al.
Publicado: (2015)

Autologous stem cell transplant (ASCT) for AIDS-related lymphoma (ARL)
por: Krishnan, A, et al.
Publicado: (2009)

A Case of Multiple Myeloma in a 17-Year-Old Girl Treated with Autologous Hematopoietic Stem Cell Transplantation (ASCT)
por: Van Man, Huynh, et al.
Publicado: (2019)

Successful autologous stem cell transplantation (ASCT) in a patient with juvenile dermatomyositis
por: Holzer, U, et al.
Publicado: (2008)

Feasibility and benefits of a structured prehabilitation programme prior to autologous stem cell transplantation (ASCT) in patients with myeloma; a prospective feasibility study
por: Mawson, Susan, et al.
Publicado: (2021)

Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma
por: Bergantim, Rui, et al.
Publicado: (2012)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Functional and Kinetic Comparison of Alanine Cysteine Serine Transporters ASCT1 and ASCT2
por: Wang, Jiali, et al.
Publicado: (2022)

Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
por: Nakaya, Aya, et al.
Publicado: (2021)

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study
por: Salmasinia, Donya, et al.
Publicado: (2010)

Ethical issues in autologous stem cell transplantation (ASCT) in advanced breast cancer: A systematic literature review
por: Droste, Sigrid, et al.
Publicado: (2011)

COVID 19 Infection in Autologous Stem Cell Transplant (ASCT) Recipients: a Single Institution Observational Cohort
por: Moreb, Jan S., et al.
Publicado: (2023)

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
por: Gregersen, Henrik, et al.
Publicado: (2021)

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation
por: Dal Bó, Suzane, et al.
Publicado: (2013)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

The role of orthodontic tooth movement in bone and root mineral density: A study of patients submitted and not submitted to orthodontic treatment
por: da Silva Campos, Marcio José, et al.
Publicado: (2012)

Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma
por: Marini, Carolina, et al.
Publicado: (2018)

Infections After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
por: Nucci, Marcio, et al.
Publicado: (2014)

VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience
por: Yıkılmaz, Aysun Şentürk, et al.
Publicado: (2020)

PB1996: TREATMENT PATHWAYS AT FIRST RELAPSE POST-ASCT IN MULTIPLE MYELOMA: IMPACT OF MAINTENANCE THERAPY ON TREATMENT OPTIONS
por: Duane, C., et al.
Publicado: (2022)

ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine‐addicted OSCC cells
por: Luo, Yijun, et al.
Publicado: (2020)

ASCT2 is the primary serine transporter in cancer cells
por: Conger, Kelly O., et al.
Publicado: (2023)

The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma
por: Pangarsa, Eko A., et al.
Publicado: (2021)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

PB1992: HISPANIC ETHNICITY AS A STRONG PREDICTOR OF POOR RESPONSE TO INDUCTION THERAPY AND ASCT IN TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
por: Chineke, I., et al.
Publicado: (2022)

Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance
por: Garnica, Marcia, et al.
Publicado: (2013)

Bacteremia in the red blood cells obtained from the cell saver in patients submitted to heart surgery
por: Luque-Oliveros, Manuel
Publicado: (2020)

Aggressive Central Nervous System Relapse after Autologous Stem Cell Transplant in Multiple Myeloma: Case Reports and Literature Review
por: Bergantim, Rui, et al.
Publicado: (2020)

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma
por: Sun, Hong-Wei, et al.
Publicado: (2016)

The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis
por: Wullenkord, Ramona, et al.
Publicado: (2021)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
por: Durie, Brian G. M., et al.
Publicado: (2020)

Voltage-dependent processes in the electroneutral amino acid exchanger ASCT2
por: Zander, Catherine B., et al.
Publicado: (2013)

Homology Modeling Informs Ligand Discovery for the Glutamine Transporter ASCT2
por: Garibsingh, Rachel-Ann A., et al.
Publicado: (2018)

Chart review across EU5 in MM post-ASCT patients
por: Ashcroft, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bdt3qq5tcf9km77pfgml5kvq49